Cargando…
Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
Chimeric antigen receptors (CARs) are engineered to target T cells specifically to tumor cells, resulting in the engineered T cell killing the tumor cell. This technology has been developed to target a range of cancers, with the most notable successes in the treatment of B-cell malignancies where fo...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387212/ https://www.ncbi.nlm.nih.gov/pubmed/37518011 http://dx.doi.org/10.1186/s12967-023-04372-4 |